MassDevice.com +5 | The top 5 medtech stories for March 2, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Analyst bearish on intermediate-risk TAVR uptake, but still sees market as positive While transcatheter aortic valve replacement technologies are on target to becoming a $5 billion market by 2021, analysts believe the path to indications for intermediate risk patients may be slower than previously expected. The market has showed a “notable step down in projected TAVR volume growth” in a set of surveys from April 2016 to Jan 2017, according to Leerink Partner analyst Danielle Antalffy. Read more 4. Amend Surgical wins FDA nod for NanoFuse BA bone graft extender Amend Surgical said today that it won 510(k) clearance from the FDA to market its NanoFuse BA as a bone graft extender for spine and orthopedic indications. The Alachua, Florida-based company’s NanoFuse BA is a composite of bioactive glass and a human demineralized bone matrix that Amend Surgical touts as providing optimal surgical handling performance and graft stability. Read more 3. Tandem claims 1st remote software update for insulin pump Tandem Diabetes Care said today that it released a software u...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news